对携带致病性BRCA1/2变异男性进行低阈值前列腺特异性抗原筛查
2014至2023年纳入340名携带可能致病/致病性BRCA1/2变异男性进行年度PSA筛查并采用年龄特异性低PSA活检阈值,7年时原发活检累积发生率为37%(95CI:31‒43),前列腺癌诊断发生率为11%(95CI:7.1‒15),转诊男性前列腺癌诊断可能性为丹麦普通男性人群的7.8倍(95CI:5.3‒11,p < 0.001)。
要点
- 携带可能致病/致病性BRCA1/2变异男性7年前列腺癌诊断累积发生率为11%(95CI:7.1‒15)。
- 转诊男性前列腺癌诊断可能性为丹麦普通男性人群的7.8倍(95CI:5.3‒11,p < 0.001)。
- 根治性前列腺切除术后4年生化失败(PSA >= 0.2 ng/ml)累积发生率为22%(95CI:2.3‒41)。
核心结论
- 携带可能致病/致病性BRCA1/2变异男性前列腺癌发生率高,但可能由低PSA活检阈值安排所解释。
- 需要更多研究将该患者人群与其他胚系特征男性进行比较。
- 根治性治疗后高复发风险令人担忧,需要进一步评估这是否为生物学现象。
研究设计与样本
- 自2014年起将携带BRCA1/2可能致病/致病性变异男性纳入前列腺特异性抗原筛查项目,进行年度PSA检测并采用年龄特异性低PSA活检阈值。
- 2014年至2023年共纳入340名男性,报告7年时的人口统计学、临床特征和治疗结局。
主要发现
- 7年时原发活检累积发生率为37%(95CI:31‒43)。
- 前列腺癌诊断发生率为11%(95CI:7.1‒15)。
- 转诊男性前列腺癌诊断可能性为丹麦普通男性人群的7.8倍(95CI:5.3‒11,p < 0.001)。
- 根治性前列腺切除术后4年生化失败(PSA >= 0.2 ng/ml)累积发生率为22%(95CI:2.3‒41)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性是并非所有男性都接受了活检前MRI。
- 需要更多研究将该患者人群与其他胚系特征男性进行比较。
- 根治性治疗后高复发风险令人担忧,需要进一步评估这是否为生物学现象。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Men with pathogenic BRCA1/2 variants are at higher risk of prostate cancer We included men with likely pathogenic/pathogenic (LP/P) variants in BRCA1/2 in a prostate-specific antigen (PSA) screening program after cascade germline testing since 2014. PSA was tested yearly and an age-specific low PSA threshold for biopsy was used, to determine if a low PSA threshold for biopsy is justified for men with pathogenic BRCA1/2 variants. METHODS: From 2014 to 2023 a total of 340 men were included in the program. We report demographics, clinical characteristics, and treatment outcomes at 7 years. RESULTS: The cumulative incidence of a primary biopsy was 37% (95CI: 31‒43) after 7 years. Incidence of prostate cancer diagnosis was 11% (95CI: 7.1‒15). Men referred were 7.8 (95CI: 5.3‒11, p < 0.001) times more likely to be diagnosed with prostate cancer than the general Danish male population. The cumulative incidence of biochemical failure (PSA > = 0.2 ng/ml) 4 years after RP was 22% (95CI: 2.3‒41). The main limitation is that not all men underwent a pre-biopsy MRI. CONCLUSION: We found a high incidence of prostate cancer in men with LP/P BRCA1/2 variants, but this may be explained by the low PSA threshold for scheduling biopsies. More studies are needed to compare this patient population to men with other germline features. The high risk of recurrence after curative therapy is worrisome and requires further evaluation as to whether this is a biological phenomenon.
引用
- Stroomberg HV, Brasso K, Blak AA, et al. Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants. Prostate Cancer Prostatic Dis. 2025. PMID: 39838196. doi:10.1038/s41391-025-00938-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。